Blue Fin Group today announced a new market research study video assessing current and future payer management in oncology including influences on payer decision-making to prefer drugs in oncology, top barriers and influencers to manage oncolytics, and oncology management expectations in the next three years, including increasing contracting for preference and value-based contracting.
Blue Fin Group announced the availability of an in-depth video by Principal Consultant Timothy Paine that explores the Public Health Service 340B program, its evolution over 30 years, and what is expected in the coming decade.
Four IntegriChain Contracts & Pricing experts will speak at two upcoming conferences: the Medicaid and Government Pricing Congress, being held in person May 23-25 and virtually June 1-2, and the Life Sciences Commercial Contracts and Chargebacks Conference, being held as a hybrid event May 24-25.
IntegriChain opens registration to all pharma manufacturers for the Access Insights Conference 2022, now co-hosted by Blue Fin Group, an IntegriChain Company. The Access Insights Conference will be held October 17-19, 2022, at the Marriott Baltimore Harborside. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature industry executive and practitioner panels, exclusive ICyte Benchmarks presentations, and strategic and tactical programs focused on driving patient access and therapy commercialization.
Blue Fin Group, a full-service management consulting firm to the pharmaceutical industry, today announced the promotion of Reena K. Patel to Partner.
IntegriChain Gross-to-Net (GTN) and Life Sciences accounting expert Jen Sharpe will present at Informa’s upcoming Life Sciences Accounting and Reporting Conference.
IntegriChain announced key promotions on its executive leadership team following its recent rapid growth: Josh Halpern is now President and Chief Operating Officer (COO); Brad Burget is now Chief Technology Officer (CTO); Vickie Koshushchenko is now Chief People Officer; and William Roth is General Manager and Managing Partner of Blue Fin Group, an IntegriChain Company.
IntegriChain has acquired Blue Fin Group, a full-service professional management consulting firm delivering research, strategy, and implementation services to help manufacturers optimize access. Blue Fin Group’s team of nearly 45 consultants and professionals with expertise in market access, drug commercialization, channel strategy, patient funnel pull through, and GTN optimization will operate as an independent division of IntegriChain.
IntegriChainhas secured leadership in State Price Transparency Reporting for Life Sciences manufacturers. Nearly 80 Life Sciences manufacturer customers rely on IntegriChain’s team of 12 subject matter experts on staff to advise and implement reporting programs. In addition, IntegriChain has generated more than 500 reports to state agencies on behalf of its Life Sciences manufacturer customers to meet the transparency requirements.
